Genitourinary Cancers

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Patients with advanced renal cell carcinoma who received lenvatinib plus pembrolizumab experienced a longer time to progression on next line of therapy compared with those who received sunitinib.

Adjuvant everolimus significantly improved recurrence-free survival when compared with placebo in patients with very high-risk renal cell carcinoma.

Experts discuss how they sequence I/O–TKI treatments for advanced renal cell carcinoma.

Elan Diamond, MD, explains toxicities commonly seen with I/O–TKI combination regimens, how to manage them, and how to discuss toxicities with patients with advanced renal cell carcinoma.

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Chung-Han Lee, MD, PhD, explains the historical barriers to treatment developments in non-clear cell renal cell carcinoma; highlights the efficacy of cabozantinib plus nivolumab in patients with unclassified, translocation, papillary, and fumarate hydratase–deficient non-clear cell renal cell carcinoma; and elaborates on the need for increased molecular classification of the histologic subsets of non-clear cell renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.

Sia Daneshmand MD, discusses emerging treatments in bladder cancer.

A review of the first-line I/O-TKI combination regimens available for advanced RCC and selecting the right patients and dose for treatment with lenvatinib and pembrolizumab.

Robert Alter, MD, presents the patient profile of a 56-year-old man with metastatic clear cell renal cell carcinoma presenting with chromaturia.

The combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.

Kevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.

The panel concludes with final thoughts on unmet needs and future perspectives for the treatment of advanced clear-cell RCC.

Dr Bilen discusses the potential use of cabozantinib as a first-line therapy in patients who receive immunotherapy in the adjuvant setting.

Dr Barata comments on sequencing therapies in the second line and beyond in patients with advanced RCC.

Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.

Mark T. Fleming, MD, discusses the phase 3 KEYNOTE-426 trial in advanced or metastatic renal cell carcinoma.

Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab plus axitinib for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.

Neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

Philippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.

Ulka Nitin Vaishampayan, MBBS, discusses the design of the phase 3 PROBE trial in advanced renal cell carcinoma.

The combination of cabozantinib plus nivolumab demonstrated promising objective response rates in patients with non–clear cell renal cell carcinoma with prominent papillary features.

Drs Zhang and Ornstein discuss regimens for advanced clear-cell RCC in the second-line setting and beyond, focusing on the METEOR, CABOSEQ,TIVO-3 CHeckMate 025, and AXIS trials.

Dr Ornstein describes how the choice of neoadjuvant therapy can impact subsequent treatment selection in advanced RCC.